Dr. Trabulsi Defines Locally Advanced Prostate Cancer

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, defines locally advanced prostate cancer.

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, defines locally advanced prostate cancer.

In defining a tumor as locally advanced, clinicians generally look at tumor parameters, such as clinical stage on a rectal exam, prostate-specific antigen (PSA), and Gleason score. These factors give an idea of a given patient’s risk category, Trabulsi says.

That information, plus imaging is used to determine whether a patient’s demonstrable disease outside of the prostate is high risk enough to lead to a strong prediction of locally advanced disease. This is done by inspecting results of imaging or a physical exam, Trabulsi explains.

For high-risk patients with locally advanced prostate cancer, researchers at Thomas Jefferson University Hospital are conducting a trial assessing cabazitaxel (Jevtana) in combination with hormone therapy and radiotherapy (NCT01420250).